253 related articles for article (PubMed ID: 11223377)
1. Ovarian rescue/protection from chemotherapeutic agents.
Blumenfeld Z
J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
[TBL] [Abstract][Full Text] [Related]
2. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
Blumenfeld Z
Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
[TBL] [Abstract][Full Text] [Related]
3. Fertility after treatment for Hodgkin's disease.
Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
[TBL] [Abstract][Full Text] [Related]
4. Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity.
Blumenfeld Z; Ritter M; Shen-Orr Z; Shariki K; Ben-Shahar M; Haim N
Am J Reprod Immunol; 1998 Jan; 39(1):33-40. PubMed ID: 9458932
[TBL] [Abstract][Full Text] [Related]
5. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women.
Blumenfeld Z; Avivi I; Ritter M; Rowe JM
J Soc Gynecol Investig; 1999; 6(5):229-39. PubMed ID: 10554760
[TBL] [Abstract][Full Text] [Related]
6. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
7. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
Blumenfeld Z; Eckman A
J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
10. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
11. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
Blumenfeld Z; Avivi I; Linn S; Epelbaum R; Ben-Shahar M; Haim N
Hum Reprod; 1996 Aug; 11(8):1620-6. PubMed ID: 8921104
[TBL] [Abstract][Full Text] [Related]
12. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.
Bedaiwy MA; Abou-Setta AM; Desai N; Hurd W; Starks D; El-Nashar SA; Al-Inany HG; Falcone T
Fertil Steril; 2011 Mar; 95(3):906-14.e1-4. PubMed ID: 21145541
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
15. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Curr Opin Obstet Gynecol; 2003 Oct; 15(5):359-70. PubMed ID: 14501238
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
[TBL] [Abstract][Full Text] [Related]
17. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
Badawy A; Elnashar A; El-Ashry M; Shahat M
Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
[TBL] [Abstract][Full Text] [Related]
19. GnRH-agonists in fertility preservation.
Blumenfeld Z
Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):523-8. PubMed ID: 18971681
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
